Literature DB >> 8126256

Absorption of danazol after administration to different sites of the gastrointestinal tract and the relationship to single- and double-peak phenomena in the plasma profiles.

W N Charman1, M C Rogge, A W Boddy, W H Barr, B M Berger.   

Abstract

The absorption of danazol (100 mg) after oral or intraintestinal administration to the proximal jejunum or proximal ileum has been studied in healthy female subjects. The extent of danazol absorption after administration as a solubilized glycerol mono-oleate emulsion formulation was approximately twofold and fourfold greater after oral dosing when compared with jejunal or ileal administration, respectively. Although not statistically significant in this study, the extent of absorption after jejunal administration was generally greater than after ileal administration. After oral dosing, qualitative assessment identified the presence of double peaks or major shouldering characteristics in 14 of the 16 individual danazol plasma concentration-time profiles, whereas only single peaks were present after intraintestinal administration. These data are consistent with the double peaking phenomena after oral administration of the emulsion formulation being stomach-related. The double peaking effect may be explained in terms of a probable combination of gastric emptying regulated absorption (due to the presence of the lipid in the emulsion formulation) and the dependence of danazol solubility on bile salt solubilization within the upper small intestine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8126256     DOI: 10.1002/j.1552-4604.1993.tb03921.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  12 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

Review 2.  Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy.

Authors:  Brahma N Singh; Bimal K Malhotra
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 3.  The use of gastrointestinal intubation studies for controlled release development.

Authors:  Steven C Sutton
Journal:  Br J Clin Pharmacol       Date:  2009-09       Impact factor: 4.335

4.  Absorption of propranolol in humans following oral, jejunal, and ileal administration.

Authors:  A Buch; W H Barr
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

5.  Cocrystal Solubilization in Biorelevant Media and its Prediction from Drug Solubilization.

Authors:  Maya P Lipert; Lilly Roy; Scott L Childs; Naír Rodríguez-Hornedo
Journal:  J Pharm Sci       Date:  2015-09-21       Impact factor: 3.534

6.  The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen.

Authors:  Werner Weitschies; Annika Bernsdorf; Thomas Giessmann; Michael Zschiesche; Christiane Modess; Vera Hartmann; Claudia Mrazek; Danilo Wegner; Stefan Nagel; Werner Siegmund
Journal:  Pharm Res       Date:  2005-05-17       Impact factor: 4.200

7.  The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids.

Authors:  Eva M Persson; Ann-Sofie Gustafsson; Anders S Carlsson; Ralf G Nilsson; Lars Knutson; Patrick Forsell; Gunilla Hanisch; Hans Lennernäs; Bertil Abrahamsson
Journal:  Pharm Res       Date:  2005-10-30       Impact factor: 4.200

8.  Appearance of double peaks in plasma concentration-time profile after oral administration depends on gastric emptying profile and weight function.

Authors:  Yukiko Metsugi; Yoshihiro Miyaji; Ken-ichi Ogawara; Kazutaka Higaki; Toshikiro Kimura
Journal:  Pharm Res       Date:  2007-10-23       Impact factor: 4.200

9.  Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs.

Authors:  E Galia; E Nicolaides; D Hörter; R Löbenberg; C Reppas; J B Dressman
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

10.  Vaginal Suppositories Containing SHetA2 to Treat Cervical Dysplasia: Pharmacokinetics of Daily Doses and Preliminary Safety Profile.

Authors:  Sanjida Mahjabeen; Manolya Kukut Hatipoglu; Stanley D Kosanke; David Garcia-Contreras; Doris M Benbrook; Lucila Garcia-Contreras
Journal:  J Pharm Sci       Date:  2020-02-27       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.